Synthesis of SMT022357 enantiomers and in vivo evaluation in a Duchenne muscular dystrophy mouse model

Following on from ezutromid, the first-in-class benzoxazole utrophin modulator that progressed to Phase 2 clinical trials for the treatment of Duchenne muscular dystrophy, a new chemotype was designed to optimise its physicochemical and ADME profile. Herein we report the synthesis of SMT022357, a se...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Tetrahedron
Hauptverfasser: Babbs, Arran, Berg, Adam, Chatzopoulou, Maria, Davies, Kay E., Davies, Stephen G., Edwards, Benjamin, Elsey, David J., Emer, Enrico, Figuccia, Aude L.A., Fletcher, Ai M., Guiraud, Simon, Harriman, Shawn, Moir, Lee, Robinson, Neil, Rowley, Jessica A., Russell, Angela J., Squire, Sarah E., Thomson, James E., Tinsley, Jonathon M., Wilson, Francis X., Wynne, Graham M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Pergamon Press 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7369641/
https://ncbi.nlm.nih.gov/pubmed/32713969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tet.2019.130819
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge